B2M and melanoma: Moreover, two other in vivo genome-wide CRISPR/Cas9 screening studies showed that deletion of APP-related genes in two different cancer models is associated with increased sensitivity to ICI-based immunotherapy, in which ERAP1, calreticulin and tapasin were the most relevant molecules in melanoma, while β2m was in renal carcinoma [58, 59].